![Samir Chandrakant Patel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Samir Chandrakant Patel
Director/Miembro de la Junta en ARVO Foundation for Eye Research .
Cargos activos de Samir Chandrakant Patel
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ARVO Foundation for Eye Research | Director/Miembro de la Junta | - | - |
Historial de carrera de Samir Chandrakant Patel
Antiguos cargos conocidos de Samir Chandrakant Patel.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
IVERIC BIO, INC. | Director/Miembro de la Junta | 29/05/2013 | 13/01/2017 |
Fundador | 18/12/2009 | 13/01/2017 | |
Presidente | 05/01/2007 | 13/01/2017 | |
KIORA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | - | - |
AERIE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Mimetogen Pharmaceuticals, Inc.
![]() Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Director/Miembro de la Junta | - | - |
Oldtech, Inc.
![]() Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Director/Miembro de la Junta | 01/01/2000 | - |
Director Técnico/Científico/I+D | 01/01/2000 | - | |
Fundador | 01/01/2000 | - | |
The University of Chicago | Corporate Officer/Principal | 01/01/1991 | - |
Formación de Samir Chandrakant Patel.
Boston University | Undergraduate Degree |
UMass Chan Medical School | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 8 |
Canadá | 2 |
Israel | 2 |
Operativa
Director/Board Member | 5 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sectorial
Health Technology | 6 |
Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
KIORA PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 5 |
---|---|
IVERIC bio, Inc.
![]() IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Oldtech, Inc.
![]() Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
Mimetogen Pharmaceuticals, Inc.
![]() Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Health Technology |
Aerie Pharmaceuticals, Inc.
![]() Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
ARVO Foundation for Eye Research |